Research  Clinical Trials

Our Services:

• Clinical Trial Management: At The Espinosa Neuroscience Institute Research Center, we manage all phases of clinical trials, from study design and patient recruitment to data analysis and reporting. Our experienced team ensures that trials are conducted with the utmost rigor and compliance.

• Patient Recruitment and Retention: We excel in identifying and enrolling suitable participants for clinical trials, ensuring diversity and representation. Our strategies enhance patient retention, which is critical for the success of any trial.

• Regulatory Compliance: We navigate the complex regulatory landscape, ensuring that all trials are conducted in strict compliance with local and international guidelines and standards.

• Data Management and Analysis: Our experts collect, manage, and analyze data with precision, providing valuable insights to our clients and helping them make informed decisions.

• Consultation and Study Design: We offer consultancy services to design, plan, and optimize clinical trials, ensuring they are efficient, scientifically sound, and cost-effective.

• Medical Writing: Our team provides comprehensive medical writing services, including protocol development, informed consent forms, and clinical study reports that adhere to regulatory requirements.

Why Choose Us:

• Expertise: Our team of experienced professionals includes clinical research experts, data scientists, and regulatory specialists who are dedicated to ensuring the success of each clinical trial.

• Ethical Practices: We uphold the highest ethical standards in all our research activities, prioritizing the safety and well-being of trial participants.

• Innovation: We embrace the latest technologies and methodologies to optimize trial efficiency, data quality, and patient engagement.

• Commitment to Science: The Espinosa Neuroscience Institute Research Center is committed to advancing medical knowledge and improving patient care. We actively engage in research that can benefit patients and society as a whole.

• Client-Centric Approach: We work closely with our clients to understand their specific needs and tailor our services to meet their goals and objectives.

Current Clinical Trials: Actively Enrolling 

Alzheimer’s Disease.

Sponsor: Biogen

Protocol Name: Envision

Protocol Title: A Phase 3b/4 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab in Participants with Alzheimer’s Disease.

Study Purpose: The purpose of this study is to verify the clinical benefit of aducanumab compared with placebo in participants with Alzheimer’s disease, including those with MCI due to Alzheimer’s disease or mild Alzheimer’s disease dementia.

STROKE - Upper Limb Spasticity

Sponsor: Ipsen Pharma

Protocol Name: DIRECTION

Protocol Title: A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity

Study Purpose: The purpose of this study is to compare the safety and efficacy of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A), which have been investigated and demonstrated in phase III trials versus placebo. 

MULTIPLE SCLEROSIS

Sponsor: Novartis

Protocol Name: COMB157GUS10

Protocol Title: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes

Study Purpose: The purpose of this study is to complement the ofatumumab clinical development pivotal trials through clinical and MRI efficacy in a treatment naïve, young adult, in early MS patient population.

DEMENTIA

Sponsor: American College of Radiology

Protocol Name: NCT04426539 New IDEAS: Imaging Dementia-Evidence for Amyloid Scanning Study

Protocol Title: A Study to Improve Precision in Amyloid PET Coverage and Patient Care through the evaluation of 12-month outcomes for amyloid positive versus amyloid negative patients.

Study Purpose: Aim 1: To compare 12-month claims-derived health outcomes in amyloid PET-positive versus amyloid PET-negative individuals presenting with MCI and dementia in the entire study cohort of diverse Medicare beneficiaries. Aim 2: To describe the association of amyloid PET findings with changes in patient management and 12–month claims-derived health outcomes among Blacks/African Americans, Latinx/Hispanics and Whites/Caucasians presenting with MCI and dementia. Aim 3: To describe the association of amyloid PET findings with changes in management and 12-month claims-derived health outcomes in individuals presenting with typical (progressive amnestic) versus atypical clinical presentations of MCI and AD dementia. 

Contact Us: 

Join us in the pursuit of scientific advancement and better healthcare outcomes. To explore how we can assist with your clinical trial needs or to learn more about our services, please contact us at 

561-788-7545.

Make a difference in healthcare through the power of clinical research with The Espinosa Neuroscience Institute EZR Research Center - Where Science Meets Progress in Clinical Trials.

Office Location:

Research Office Location:

801 Meadows Rd Suite 103

Boca Raton FL 33432